Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Division of Clinical Neurosciences, University of Turku, Turku, Finland; Neurocenter Turku, University Hospital, Turku, Finland.
Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Division of Clinical Neurosciences, University of Turku, Turku, Finland; Neurocenter Turku, University Hospital, Turku, Finland.
Mult Scler Relat Disord. 2023 Jul;75:104755. doi: 10.1016/j.msard.2023.104755. Epub 2023 May 10.
Factors driving increased innate immune cell activation in multiple sclerosis (MS) brain are not well understood. As higher prevalence of microglial/macrophage activation in association with chronic lesions and diffusely in the normal appearing white matter predict more rapid accumulation of clinical disability, it is of high importance to understand processes behind this. Objective of the study was to explore demographic, clinical and paraclinical variables associating with later positron emission tomography (PET)-measurable innate immune cell activation.
PET-imaging using a TSPO-binding [C]PK11195 was performed to evaluate microglial activation in patients with relapsing-remitting MS aged 40-55 years with a minimum disease duration of five years (n = 37). Medical records and diagnostic MR images were reviewed for relevant early MS disease-related clinical and paraclinical parameters.
More prominent microglial activation was associated with higher number of T2 lesions in the diagnostic MRI, a higher immunoglobulin G (IgG) index in the diagnostic CSF and Expanded Disability Status Scale (EDSS) ≥ 2.0 five years after diagnosis.
The number of T2 lesions in MRI, and CSF immunoglobulin content measured by IgG index at the time of MS diagnosis associated with later TSPO-PET-measurable innate immune cell activation. This suggests that both focal and diffuse early inflammatory phenomena impact the development of later progression-related pathology.
多发性硬化症(MS)大脑中导致固有免疫细胞激活增加的因素尚不清楚。由于与慢性病变相关的以及在正常表现的白质中弥漫存在的更高水平的小胶质细胞/巨噬细胞激活预示着更快的临床残疾累积,因此了解这背后的过程非常重要。本研究的目的是探索与随后的正电子发射断层扫描(PET)可测量的固有免疫细胞激活相关的人口统计学、临床和临床前变量。
对年龄在 40-55 岁、疾病持续时间至少为五年的复发缓解型 MS 患者(n=37)使用 TSPO 结合[C]PK11195 进行 PET 成像,以评估小胶质细胞激活。回顾了病历和诊断性磁共振成像(MRI),以获取相关的早期 MS 疾病相关的临床和临床前参数。
更明显的小胶质细胞激活与诊断性 MRI 中的 T2 病变数量较多、诊断性 CSF 中的 IgG 指数较高以及诊断后五年的扩展残疾状态量表(EDSS)≥2.0 相关。
MRI 中的 T2 病变数量以及 MS 诊断时 CSF 免疫球蛋白含量(通过 IgG 指数测量)与随后的 TSPO-PET 可测量的固有免疫细胞激活相关。这表明早期的局灶性和弥漫性炎症现象都影响了后期进展相关病理的发展。